Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)

NCT ID: NCT05475366

Last Updated: 2025-09-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-12
• Study Completion Date: 2028-12-11

Brief Summary

The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1). Chemotherapy regimen (FOLFIRINOX vs Gem-nabP) will be selected based on transcriptomic signatures applied to the pre-therapeutic liver biopsy of newly diagnosed PDAC patients.

Detailed Description

Step 1: patients will sign a 1st informed consent prospectively for the molecular screening (RNAseq profile). 5 transcriptomic signatures will be applied for prediction of response to 5 Fluoro-Uracil (5FU), oxaliplatin, irinotecan, gemcitabine and taxane. Biomarker status will be obtained for all patients as part of good clinical practice.

Patients will be eligible for prospective step 2 only if the transcriptomic analysis is informative and the treatment can be started within 28 days.

Step 2: study treatment strategy: based on the results of transcriptomic signatures, patients will receive either FOLFIRINOX or Gem-nabP according to the following algorithm (2nd informed consent):

• Predicted to be FOLFIRINOX sensitive (regardless of sensitivity to Gem-nabP) = FOLFIRINOX
• Predicted to be FOLFIRINOX and Gem-nabP resistant = FOLFIRINOX
• Presence of a germline breast cancer (BRCA) mutation (regardless of transcriptomic signature) = FOLFIRINOX (tumors sensitive to platinum).
• Predicted to be Gem-nabP sensitive and FOLFIRINOX resistant = Gem-nabP

Chemotherapy with FOLFIRINOX and Gemcitabine plus nab-paclitaxel will be administered as in routine practice, according to their approval. Dose adaptation will be allowed according to investigator's usual practice.

Conditions

Carcinoma, Pancreatic Ductal; Prognosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Molecular screening for prediction of response

L1 chemotherapy regimen (FOLFIRINOX vs Gemcitabine plus nab-paclitaxel (GemnabP)) will be selected based on transcriptomic signatures applied to the pre-therapeutic biopsy of newly diagnosed PDAC patients.

Group Type: EXPERIMENTAL

Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC

Intervention Type: OTHER

Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.

Biomarkers of tumor signatures (translational studies)

Intervention Type: OTHER

Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy

Interventions

Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC

Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.

Intervention Type: OTHER

Biomarkers of tumor signatures (translational studies)

Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.

2. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

3. Histologically or cytologically proven Pancreatic Ductal Adenocarcinoma (PDAC).

4. Metastatic disease.

5. Measurable or evaluable lesions according to RECIST v1.1 criteria.

6. First-line therapy (previous neoadjuvant/adjuvant chemotherapy not allowed).

7. Age ≥ 18 years (no upper limit, patients ≥ 75 years old must have a G8 score ≥ 14).

8. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.

9. Availability of tumor tissue sample from the primary pancreatic tumor or liver metastasis (chemo-naïve) before inclusion in step 1.

10. Adequate organ function, as defined by the following (blood test ≤ 7 days prior to inclusion):

1. Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (≤ 5 ULN in case of liver metastases)

2. Total serum bilirubin ≤ 1.5 ULN

3. Serum albumin ≥ 28 g/L

4. Hemoglobin ≥ 9.0 g/dl

5. Absolute neutrophil count (ANC) ≥ 1,500/μL

6. Platelets ≥ 100,000/μL

7. Creatinine clearance ≥ 50 mL/min (MDRD).

11. No Dihydropyrimidine dehydrogenase (DPD) deficiency (normal uracil level).

12. Life expectancy ≥ 3 months.

13. a. Evidence of post-menopausal status b. (or) negative urinary or serum pregnancy test for female pre-menopausal patients.

14. Registration in a National Health Care System.

Exclusion Criteria

1. Concurrent enrolment in another interventional clinical study.

2. Previous treatment with chemotherapy for pancreatic cancer.

3. Uncontrolled massive pleural effusion or massive ascites.

4. Known deficiency in UGT1A1 (homozygous UGT1A1*28 allele).

5. Active bacterial, viral, or fungal infection requiring systemic therapy, including tuberculosis, hepatitis B (known positive Hepatitis B Virus surface antigen (HBsAg) result), hepatitis C (with positive RNA), Sars-Cov-2 or human immunodeficiency virus (positive HIV 1/2 antibodies).

6. Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.

7. Known active central nervous system metastases and/or carcinomatous meningitis; patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline).

8. Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure or coronary disease, peripheral artery disease, severe chronic obstructive pulmonary disease, decompensated cirrhosis, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

9. Live vaccine administration within 30 days prior to the first dose of study treatment.

10. Known or suspected allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant, in the opinion of the treating investigator.

12. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.

13. Major surgical procedure (as defined by the Investigator) within 4 weeks prior to the first dose of trial treatment.

14. Pregnancy/lactation.

15. Person under legal protection or tutelage or guardianship.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut Curie

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cindy NEUZILLET, MD, PhD

Role: STUDY_DIRECTOR

Institut Curie

Locations

Hôpital Beaujon

Clichy, , France

Site Status: RECRUITING

Hôpital HENRI MONDOR

Créteil, , France

Site Status: RECRUITING

Hôpital Claude Hurriez

Lille, , France

Site Status: RECRUITING

Institut Paoli-Calmettes

Marseille, , France

Site Status: RECRUITING

CHU Robert Debré

Reims, , France

Site Status: NOT_YET_RECRUITING

Institut Curie

Saint-Cloud, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Cindy NEUZILLET, MD, PhD

Role: CONTACT

cindy.neuzillet@curie.fr

+33 1 47 11 15 15

Marie-Emmanuelle Legrier

Role: CONTACT

drci.promotion@curie.fr

Facility Contacts

Louis DE MESTIER, MD

Role: primary

Charlotte FENIOUX, MD

Role: primary

Antony TURPIN, MD

Role: primary

Brice CHANEZ, MD

Role: primary

Olivier BOUCHE, MD

Role: primary

Cindy NEUZILLET, MD, PhD

Role: primary

Other Identifiers

IC 2021-15

Identifier Type: -

Identifier Source: org_study_id